Theagene Jean-Manasse, a director at MAIA Biotechnology, Inc., has exercised stock options for 32,012 shares of the company. This transaction, reported on October 2, 2026, is significant as it demonstrates the confidence of a key executive in the company's future prospects.
Background
MAIA Biotechnology, Inc. operates in the pharmaceutical preparations industry, focusing on innovative treatments. The company is incorporated in Delaware and has its business address in Chicago, Illinois. It trades under the ticker symbol MAIA.
What the Filing Says
The filing indicates that Jean-Manasse exercised stock options on September 30, 2026, at an exercise price of $1.18 per share. The options were granted under MAIA's 2021 Equity Incentive Plan, and they vest 100% on the date of the grant. Following this transaction, Jean-Manasse owns 32,012 shares of MAIA common stock.
Impact
This exercise of stock options may influence shareholder sentiment and market perceptions regarding the company’s leadership. It highlights the commitment of executives to the company's growth and performance, which could be viewed positively by investors.
What's Next
The filing does not say what happens next.
Details of the Stock Options
The stock options exercised by Jean-Manasse were granted under MAIA's 2021 Equity Incentive Plan. These options were fully vested on the date of the grant, September 30, 2026, allowing for immediate exercise. The expiration date for these options is set for September 30, 2036, providing a ten-year window for Jean-Manasse to exercise these options.
Ownership Structure
Following the exercise of these stock options, Jean-Manasse holds a total of 32,012 shares of MAIA common stock, indicating a direct ownership stake in the company. This ownership reflects a commitment to the company's long-term success and aligns the interests of the executive with those of the shareholders.
Company Overview
MAIA Biotechnology, Inc. is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. The company is incorporated in Delaware and operates out of its business address located at 444 West Lake Street, Suite 1700, Chicago, Illinois.
Regulatory Compliance
This filing is in compliance with the SEC Act of 1934, specifically under Form 4, which is required for reporting changes in beneficial ownership of securities. The timely submission of this report underscores the company's adherence to regulatory standards and transparency in its operations.